Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
Status:
Completed
Trial end date:
2019-06-18
Target enrollment:
Participant gender:
Summary
12 week study to assess the LDL-C lowering efficacy, other lipid and glycemic measures, and
safety of bempedoic acid/ezetimibe FDC compared to ezetimibe and placebo in patients with
type 2 diabetes (T2D) and elevated LDL-C